Literature DB >> 8940301

Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats.

H Manev1, T Uz, A Kharlamov, J Y Joo.   

Abstract

The pineal hormone melatonin is neuroprotective in vitro, and in vivo it is neuroprotective when given in pharmacological doses. Consequently, it has been hypothesized that with aging, as circulating levels of melatonin in mammals normally decrease, the brain might be at increased risk of neurodegeneration. However, direct evidence that melatonin deficiency leads to increased brain vulnerability is still lacking. We created melatonin deficiency in rats by pinealectomy and induced neurodegeneration by two models of focal brain ischemia/stroke and by glutamate receptor-mediated, epilepsy-like seizures. We observed greater neurodegeneration in melatonin-deficient animals than in controls. Our results suggest that endogenous melatonin may play a neuroprotective role, and that melatonin deficiency might be a pathophysiological mechanism in neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8940301     DOI: 10.1096/fasebj.10.13.8940301

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  28 in total

Review 1.  [Characteristic features of optic nerve ganglion cells and approaches for neuroprotection. From intracellular to capillary processes and therapeutic considerations].

Authors:  R H W Funk; K-G Schmidt
Journal:  Ophthalmologe       Date:  2004-11       Impact factor: 1.059

Review 2.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

3.  Melatonin potentiates the anticonvulsant action of phenobarbital in neonatal rats.

Authors:  Patrick A Forcelli; Colin Soper; Anne Duckles; Karen Gale; Alexei Kondratyev
Journal:  Epilepsy Res       Date:  2013-10-05       Impact factor: 3.045

Review 4.  Role of oxidative stress in epileptic seizures.

Authors:  Eun-Joo Shin; Ji Hoon Jeong; Yoon Hee Chung; Won-Ki Kim; Kwang-Ho Ko; Jae-Hyung Bach; Jau-Shyong Hong; Yukio Yoneda; Hyoung-Chun Kim
Journal:  Neurochem Int       Date:  2011-06-13       Impact factor: 3.921

Review 5.  Melatonin and Multiple Sclerosis: From Plausible Neuropharmacological Mechanisms of Action to Experimental and Clinical Evidence.

Authors:  Mahshid Yeganeh Salehpour; Adriano Mollica; Saeideh Momtaz; Nima Sanadgol; Mohammad Hosein Farzaei
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

6.  Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum.

Authors:  C J van der Schyf; K Castagnoli; S Palmer; L Hazelwood; N Castagnoli
Journal:  Neurotox Res       Date:  2000-04       Impact factor: 3.911

Review 7.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

Review 8.  Domoic acid-induced neurotoxicity in the hippocampus of adult rats.

Authors:  Ananth Chandrasekaran; Gopalakrishnakone Ponnambalam; Charanjit Kaur
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

9.  Evaluation of the role of chronic daily melatonin administration and pinealectomy on penicillin-induced focal epileptiform activity and spectral analysis of ECoG in rats: an in vivo electrophysiological study.

Authors:  Mehmet Yildirim; Selcen Aydin-Abidin; Ismail Abidin; Metehan Akca; Sinan Canpolat; Ali Cansu
Journal:  Neurochem Res       Date:  2013-05-14       Impact factor: 3.996

10.  Melatonin promotes oligodendroglial maturation of injured white matter in neonatal rats.

Authors:  Paul Olivier; Romain H Fontaine; Gauthier Loron; Juliette Van Steenwinckel; Valérie Biran; Véronique Massonneau; Angela Kaindl; Jeremie Dalous; Christiane Charriaut-Marlangue; Marie-Stéphane Aigrot; Julien Pansiot; Catherine Verney; Pierre Gressens; Olivier Baud
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.